Fermenta Biotech's Valuation Adjusted to Expensive Amid Strong Profit Growth and Sales Performance

Fermenta Biotech, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The revision in its score reflects a shift in the valuation grade, now categorized as expensive. This change is influenced by several key financial metrics that highlight the company's current market position.
The stock's price-to-earnings (PE) ratio stands at 25.51, while the price-to-book value is recorded at 3.12. Additionally, the enterprise value to EBITDA ratio is 12.71, and the enterprise value to sales ratio is 2.33. The company's return on capital employed (ROCE) is noted at 6.61%, with a return on equity (ROE) of 2.92%.

Despite these valuation metrics, Fermenta Biotech has demonstrated notable performance indicators, including a significant net profit growth of 279.28% in the latest quarter. The company has also reported its highest net sales at Rs 156.47 crore and a robust PBDIT of Rs 53.27 crore. Furthermore, promoter confidence appears strong, with a 2.03% increase in stake over the previous quarter.

Overall, while the stock has shown impressive returns over the past year, the valuation metrics suggest a premium compared to its peers.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.